Response to Spellberg and Brass.
作者信息
Solomkin Joseph S, Hershberger Ellie, Eckmann Christian
机构信息
Department of Surgery, University of Cincinnati College of Medicine, Ohio.
Clinical Research, Merck Research Laboratories, Lexington, Massachusetts.
出版信息
Clin Infect Dis. 2016 Feb 15;62(4):526. doi: 10.1093/cid/civ896. Epub 2015 Oct 20.
PMID:26486708
Abstract
摘要
相似文献
1
Response to Spellberg and Brass.对斯佩尔伯格和布拉斯的回应。
Clin Infect Dis. 2016 Feb 15;62(4):526. doi: 10.1093/cid/civ896. Epub 2015 Oct 20.
2
Noninferiority Doesn't Mean Not Inferior.非劣效性并不意味着不差劲。
Clin Infect Dis. 2016 Feb 15;62(4):525-6. doi: 10.1093/cid/civ895. Epub 2015 Oct 20.
3
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).头孢洛扎/他唑巴坦联合甲硝唑用于多重耐药时代复杂性腹腔内感染的治疗：一项随机、双盲、3期试验（ASPECT-cIAI）的结果
Clin Infect Dis. 2015 May 15;60(10):1462-71. doi: 10.1093/cid/civ097. Epub 2015 Feb 10.
4
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.基于英国细菌分离株的体外监测，比较头孢洛扎/他唑巴坦联合甲硝唑与哌拉西林/他唑巴坦作为经验性治疗复杂腹腔内感染的成本效益。
J Med Econ. 2017 Aug;20(8):840-849. doi: 10.1080/13696998.2017.1333960. Epub 2017 Jun 8.
5
Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.头孢洛扎/他唑巴坦（泽沃克赞）——一种新型静脉用抗生素。
Med Lett Drugs Ther. 2015 Mar 2;57(1463):31-3.
6
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?新型β-内酰胺/β-内酰胺酶抑制剂头孢洛扎/他唑巴坦和头孢他啶/阿维巴坦的作用是什么？
Expert Rev Anti Infect Ther. 2016 Oct;14(10):875-8. doi: 10.1080/14787210.2016.1233060.
7
Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam.重症监护病房中的新型静脉用抗生素：头孢洛林、头孢托罗-他唑巴坦和头孢他啶-阿维巴坦。
AACN Adv Crit Care. 2016 Oct;27(4):353-357. doi: 10.4037/aacnacc2016612.
8
In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.头孢洛扎-他唑巴坦对ASPECT-cIAI研究中鉴定出的厌氧生物的体外活性
Antimicrob Agents Chemother. 2015 Nov 9;60(1):666-8. doi: 10.1128/AAC.01964-15. Print 2016 Jan.
9
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.头孢洛扎/他唑巴坦治疗产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌引起的泌尿系统及腹腔内感染的疗效：3期临床试验汇总分析
J Antimicrob Chemother. 2017 Jan;72(1):268-272. doi: 10.1093/jac/dkw374. Epub 2016 Oct 5.
10
Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.为儿科患者开具头孢洛扎/他唑巴坦：现状与未来影响
Paediatr Drugs. 2016 Feb;18(1):1-11. doi: 10.1007/s40272-015-0157-x.
引用本文的文献
1
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.头孢托罗-他唑巴坦用于复杂性尿路感染和腹腔内感染的批判性评价。
Ther Clin Risk Manag. 2016 May 19;12:787-97. doi: 10.2147/TCRM.S83844. eCollection 2016.
Zotero 插件